-
Je něco špatně v tomto záznamu ?
Carltonine-derived compounds for targeted butyrylcholinesterase inhibition
F. Pidany, J. Kroustkova, J. Jenco, KH. Breiterova, L. Muckova, L. Novakova, J. Kunes, J. Fibigar, T. Kucera, M. Novak, A. Sorf, M. Hrabinova, L. Pulkrabkova, J. Janousek, O. Soukup, D. Jun, J. Korabecny, L. Cahlikova
Status neindexováno Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
NLK
PubMed Central
od 2020 do Před 1 rokem
ROAD: Directory of Open Access Scholarly Resources
od 2020
PubMed
38784455
DOI
10.1039/d4md00060a
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
The investigation into human butyrylcholinesterase (hBChE) inhibitors as therapeutic agents for Alzheimer's disease (AD) holds significant promise, addressing both symptomatic relief and disease progression. In the pursuit of novel drug candidates with a selective BChE inhibition pattern, we focused on naturally occurring template structures, specifically Amaryllidaceae alkaloids of the carltonine-type. Herein, we explored a series of compounds implementing an innovative chemical scaffold built on the 3- and 4-benzyloxy-benzylamino chemotype. Notably, compounds 28 (hBChE IC50 = 0.171 ± 0.063 μM) and 33 (hBChE IC50 = 0.167 ± 0.018 μM) emerged as top-ranked hBChE inhibitors. In silico simulations elucidated the binding modes of these compounds within hBChE. CNS availability was predicted using the BBB score algorithm, corroborated by in vitro permeability assessments with the most potent derivatives. Compound 33 was also inspected for aqueous solubility, microsomal and plasma stability. Chemoinformatics analysis validated these hBChE inhibitors for oral administration, indicating favorable gastrointestinal absorption in compliance with Lipinski's and Veber's rules. Safety assessments, crucial for the chronic administration typical in AD treatment, were conducted through cytotoxicity testing on human neuroblastoma (SH-SY5Y) and hepatocellular carcinoma (HepG2) cell lines.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24012725
- 003
- CZ-PrNML
- 005
- 20240726151329.0
- 007
- ta
- 008
- 240723s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1039/d4md00060a $2 doi
- 035 __
- $a (PubMed)38784455
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Pidany, Filip $u Faculty of Pharmacy in Hradec Kralove, Department of Pharmacognosy and Pharmaceutical Botany, Charles University Akademika Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic cahlikova@faf.cuni.cz
- 245 10
- $a Carltonine-derived compounds for targeted butyrylcholinesterase inhibition / $c F. Pidany, J. Kroustkova, J. Jenco, KH. Breiterova, L. Muckova, L. Novakova, J. Kunes, J. Fibigar, T. Kucera, M. Novak, A. Sorf, M. Hrabinova, L. Pulkrabkova, J. Janousek, O. Soukup, D. Jun, J. Korabecny, L. Cahlikova
- 520 9_
- $a The investigation into human butyrylcholinesterase (hBChE) inhibitors as therapeutic agents for Alzheimer's disease (AD) holds significant promise, addressing both symptomatic relief and disease progression. In the pursuit of novel drug candidates with a selective BChE inhibition pattern, we focused on naturally occurring template structures, specifically Amaryllidaceae alkaloids of the carltonine-type. Herein, we explored a series of compounds implementing an innovative chemical scaffold built on the 3- and 4-benzyloxy-benzylamino chemotype. Notably, compounds 28 (hBChE IC50 = 0.171 ± 0.063 μM) and 33 (hBChE IC50 = 0.167 ± 0.018 μM) emerged as top-ranked hBChE inhibitors. In silico simulations elucidated the binding modes of these compounds within hBChE. CNS availability was predicted using the BBB score algorithm, corroborated by in vitro permeability assessments with the most potent derivatives. Compound 33 was also inspected for aqueous solubility, microsomal and plasma stability. Chemoinformatics analysis validated these hBChE inhibitors for oral administration, indicating favorable gastrointestinal absorption in compliance with Lipinski's and Veber's rules. Safety assessments, crucial for the chronic administration typical in AD treatment, were conducted through cytotoxicity testing on human neuroblastoma (SH-SY5Y) and hepatocellular carcinoma (HepG2) cell lines.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kroustkova, Jana $u Faculty of Pharmacy in Hradec Kralove, Department of Pharmacognosy and Pharmaceutical Botany, Charles University Akademika Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic cahlikova@faf.cuni.cz
- 700 1_
- $a Jenco, Jaroslav $u Faculty of Pharmacy in Hradec Kralove, Department of Pharmacognosy and Pharmaceutical Botany, Charles University Akademika Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic cahlikova@faf.cuni.cz $1 https://orcid.org/0000000186678303
- 700 1_
- $a Breiterova, Katerina Hradiska $u Faculty of Pharmacy in Hradec Kralove, Department of Pharmacognosy and Pharmaceutical Botany, Charles University Akademika Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic cahlikova@faf.cuni.cz
- 700 1_
- $a Muckova, Lubica $u Biomedical Research Center, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic jan.korabecny@fnhk.cz $u Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic
- 700 1_
- $a Novakova, Lucie $u Faculty of Pharmacy in Hradec Kralove, Department of Analytical Chemistry, Charles University Akademika Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic $1 https://orcid.org/0000000215558870 $7 xx0062498
- 700 1_
- $a Kunes, Jiri $u Faculty of Pharmacy in Hradec Kralove, Department of Bioorganic and Organic Chemistry, Charles University Akademika Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic
- 700 1_
- $a Fibigar, Jakub $u Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic
- 700 1_
- $a Kucera, Tomas $u Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic
- 700 1_
- $a Novak, Martin $u Biomedical Research Center, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic jan.korabecny@fnhk.cz
- 700 1_
- $a Sorf, Ales $u Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic
- 700 1_
- $a Hrabinova, Martina $u Biomedical Research Center, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic jan.korabecny@fnhk.cz $u Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic
- 700 1_
- $a Pulkrabkova, Lenka $u Biomedical Research Center, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic jan.korabecny@fnhk.cz $u Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic
- 700 1_
- $a Janousek, Jiri $u Biomedical Research Center, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic jan.korabecny@fnhk.cz
- 700 1_
- $a Soukup, Ondrej $u Biomedical Research Center, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic jan.korabecny@fnhk.cz $u Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic
- 700 1_
- $a Jun, Daniel $u Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic $1 https://orcid.org/0000000208826304 $7 xx0040498
- 700 1_
- $a Korabecny, Jan $u Biomedical Research Center, University Hospital Hradec Kralove Sokolska 581 500 05 Hradec Kralove Czech Republic jan.korabecny@fnhk.cz $u Military Faculty of Medicine, Department of Toxicology and Military Pharmacy, University of Defence Trebesska 1575 500 01 Hradec Kralove Czech Republic $1 https://orcid.org/0000000169777596 $7 xx0119837
- 700 1_
- $a Cahlikova, Lucie $u Faculty of Pharmacy in Hradec Kralove, Department of Pharmacognosy and Pharmaceutical Botany, Charles University Akademika Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic cahlikova@faf.cuni.cz $1 https://orcid.org/0000000215558870 $7 xx0062498
- 773 0_
- $w MED00208004 $t RSC medicinal chemistry $x 2632-8682 $g Roč. 15, č. 5 (2024), s. 1601-1625
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38784455 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240723 $b ABA008
- 991 __
- $a 20240726151321 $b ABA008
- 999 __
- $a ok $b bmc $g 2125457 $s 1224588
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 15 $c 5 $d 1601-1625 $e 20240322 $i 2632-8682 $m RSC medicinal chemistry $n RSC Med Chem $x MED00208004
- LZP __
- $a Pubmed-20240723